• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Thrombotic thrombocytopenic purpura with juvenile systemic lupus erythematosus: successful treatment with caplacizumab and rituximab.

作者信息

Yokoyama Tadafumi, Mimura Takuya, Tanaka Hiroki, Kasahara Ria, Usami Masaaki, Matsuda Yusuke, Fujiki Toshihiro, Wada Taizo

机构信息

Department of Pediatrics, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, 920-8640, Ishikawa, Japan.

Department of Pediatrics, National Hospital Organization, Kanazawa Medical Center, Shimoishiibiki-machi 1-1, Kanazawa, 920-8650, Ishikawa, Japan.

出版信息

Pediatr Rheumatol Online J. 2024 Dec 18;22(1):106. doi: 10.1186/s12969-024-01049-0.

DOI:10.1186/s12969-024-01049-0
PMID:39696445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11654370/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e2/11654370/8aa8cf947329/12969_2024_1049_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e2/11654370/f442d2b247eb/12969_2024_1049_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e2/11654370/8aa8cf947329/12969_2024_1049_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e2/11654370/f442d2b247eb/12969_2024_1049_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e2/11654370/8aa8cf947329/12969_2024_1049_Fig2_HTML.jpg

相似文献

1
Thrombotic thrombocytopenic purpura with juvenile systemic lupus erythematosus: successful treatment with caplacizumab and rituximab.血栓性血小板减少性紫癜合并青少年系统性红斑狼疮：使用卡泊单抗和利妥昔单抗成功治疗
Pediatr Rheumatol Online J. 2024 Dec 18;22(1):106. doi: 10.1186/s12969-024-01049-0.
2
Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.卡泊单抗第二疗程成功用于复发性血栓性血小板减少性紫癜
Platelets. 2022 Jul 4;33(5):790-791. doi: 10.1080/09537104.2021.1981851. Epub 2021 Sep 26.
3
Delayed Recovery of a Disintegrin-Like and Metalloproteinase With Thrombospondin Type 1 Motif 13 (ADAMTS13) Activity in Immune Thrombotic Thrombocytopenic Purpura Treated With Caplacizumab and Rituximab.在接受卡泊单抗和利妥昔单抗治疗的免疫性血栓性血小板减少性紫癜中，含血小板反应蛋白基序的解聚素样金属蛋白酶13（ADAMTS13）活性延迟恢复
Cureus. 2025 Feb 12;17(2):e78884. doi: 10.7759/cureus.78884. eCollection 2025 Feb.
4
Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).成功治疗三例自身免疫性血栓性血小板减少性紫癜患者，治疗方案为：卡普昔单抗、皮质类固醇、血浆置换、利妥昔单抗和静脉注射免疫球蛋白（CASPERI）。
Transfus Apher Sci. 2021 Feb;60(1):103011. doi: 10.1016/j.transci.2020.103011. Epub 2020 Nov 7.
5
Refining the standard of care in immune thrombotic thrombocytopenic purpura.规范免疫性血栓性血小板减少性紫癜的治疗标准。
Clin Adv Hematol Oncol. 2024 Oct;22(8):381-391.
6
Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus.病例报告：红斑狼疮患者接种狂犬病疫苗后引发血栓性血小板减少性紫癜。
Front Immunol. 2022 Apr 25;13:851316. doi: 10.3389/fimmu.2022.851316. eCollection 2022.
7
Thrombotic thrombocytopenic purpura that developed 3 years after systemic lupus erythematosus had remitted with rituximab therapy.血栓性血小板减少性紫癜在系统性红斑狼疮经利妥昔单抗治疗缓解 3 年后发生。
Mod Rheumatol Case Rep. 2023 Dec 29;8(1):57-62. doi: 10.1093/mrcr/rxad032.
8
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.儿童期和青少年期起病的获得性血栓性血小板减少性紫癜伴严重ADAMTS13缺乏症：法国全国血栓性微血管病登记处的一项队列研究
Lancet Haematol. 2016 Nov;3(11):e537-e546. doi: 10.1016/S2352-3026(16)30125-9. Epub 2016 Oct 3.
9
Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan.在日本进行的一项2/3期研究的事后分析：利妥昔单抗的一线使用可能预防免疫性血小板减少性紫癜患者在接受卡泊西单抗治疗期间ADAMTS13抑制剂活性增强。
Thromb J. 2024 Aug 2;22(1):72. doi: 10.1186/s12959-024-00642-3.
10
Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report.卡泊单抗成功治疗难治性血栓性血小板减少性紫癜（TTP）：一例报告
Cureus. 2023 Jul 25;15(7):e42423. doi: 10.7759/cureus.42423. eCollection 2023 Jul.

本文引用的文献

1
Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis.B 细胞靶向生物制剂治疗狼疮肾炎的疗效和安全性：系统评价和网络荟萃分析。
Ren Fail. 2024 Dec;46(2):2416605. doi: 10.1080/0886022X.2024.2416605. Epub 2024 Oct 23.
2
Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience.卡普拉西单抗在儿科免疫性血栓性血小板减少性紫癜中的应用：英国 TTP 登记处经验。
Blood Adv. 2024 Sep 10;8(17):4563-4567. doi: 10.1182/bloodadvances.2024013488.
3
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.
4
Thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜。
Blood. 2017 May 25;129(21):2836-2846. doi: 10.1182/blood-2016-10-709857. Epub 2017 Apr 17.
5
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.卡普雷珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.